1. Analysis of Recent Papers in Hypertension
- Author
-
Jan Basile and Michael J Bloch
- Subjects
Male ,Percutaneous ,Sodium Chloride Symporter Inhibitors ,Thiazide diuretic ,medicine.medical_treatment ,Endocrinology, Diabetes and Metabolism ,Alternative medicine ,Resistant hypertension ,Blood Pressure ,Disease ,Comorbidity ,Pharmacology ,Plasma renin activity ,Body Mass Index ,Nursing care ,Hydrochlorothiazide ,Rimonabant ,Self measurement ,Ambulatory blood pressure measurement ,Hyperlipidemia ,Diastolic function ,Prospective Studies ,Office based ,Management science ,Incidence ,Publications ,Drug Synergism ,Blood Pressure Monitoring, Ambulatory ,Chronotherapy (treatment scheduling) ,Hypokalemia ,Drug Combinations ,Italy ,Echocardiography ,Stroke prevention ,Ambulatory ,Aortic pressure ,Hypertrophy, Left Ventricular ,Cardiology and Cardiovascular Medicine ,Blood pressure control ,medicine.medical_specialty ,Ambulatory blood pressure ,Statin ,Renal function ,Library science ,Renin inhibitor ,Diabetes Complications ,White matter ,Pharmacotherapy ,Text mining ,Thinness ,Refractory ,Intervention (counseling) ,Heart rate ,Post-hoc analysis ,Diabetes Mellitus ,Humans ,Circadian rhythm ,Hormone replacement therapy ,Intensive care medicine ,Thiazide ,Aged ,Heart Failure ,Models, Statistical ,Blood Pressure Determination ,medicine.disease ,Coronary heart disease ,Self Care ,Endocrinology ,Increased risk ,Blood pressure ,Diabetes Mellitus, Type 2 ,chemistry ,ACE inhibitor ,Isolated systolic hypertension ,Potassium ,Value (mathematics) ,Blood Glucose ,Angiotensin receptor ,Pediatrics ,Office Visits ,Hemodynamics ,Coronary Disease ,Post menopausal ,Calcium channel blocker ,Type 2 diabetes ,Overweight ,Bioinformatics ,Reduction (complexity) ,chemistry.chemical_compound ,Older patients ,New onset diabetes ,Risk Factors ,Diastole ,Simple (philosophy) ,Clinical Trials as Topic ,Framingham Risk Score ,biology ,Treatment regimen ,Anticholesteremic Agents ,Health Care Costs ,Articles ,Middle Aged ,Clinical judgment ,Hyperaldosteronism ,Complement (complexity) ,Pulse pressure ,medicine.anatomical_structure ,Treatment Outcome ,Anesthesia ,Hypertension ,Cardiology ,Chlorthalidone ,Female ,Radiology ,Medical emergency ,medicine.symptom ,Current (fluid) ,Cardiovascular outcomes ,medicine.drug ,Adult ,Systole ,medicine.drug_class ,Future risk ,MEDLINE ,Hyperlipidemias ,Prehypertension ,Double-Blind Method ,Internal medicine ,Diabetes mellitus ,Cholesterylester transfer protein ,Atherosclerotic renal artery stenosis ,medicine ,Internal Medicine ,Albuminuria ,In patient ,Obesity ,Angiotensin receptor antagonist ,Survival rate ,Reduction (orthopedic surgery) ,Antihypertensive Agents ,Blood pressure management ,business.industry ,Torcetrapib ,Potassium, Dietary ,Total mortality ,Emergency medicine ,Vascular resistance ,biology.protein ,Physical therapy ,Microalbuminuria ,business ,Medical therapy ,Kidney disease - Abstract
A prespecified objective of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) was to assess whether any synergistic effects were apparent between the lipid-lowering and blood-pressure-lowering regimens in preventing cardiovascular events.A total of 19 257 hypertensive subjects were randomized to an amlodipine-based regimen or an atenolol-based regimen. Of these, 10 305 subjects with total cholesterolor =6.5 mmol/L were further randomized to atorvastatin 10 mg daily or placebo. In this analysis, the effects of atorvastatin were compared with placebo on coronary heart disease (CHD), cardiovascular and stroke events in those assigned amlodipine-based and atenolol-based regimens. In the ASCOT lipid-lowering arm (LLA), overall, atorvastatin reduced the relative risk of the primary endpoint of non-fatal myocardial infarction and fatal CHD events by 36% (HR 0.64, CI 0.50-0.83, P=0.0005), total cardiovascular events by 21% (HR 0.79, CI 0.69-0.90, P=0.0005), and stroke by 27% (HR 0.73, CI 0.56-0.96, P=0.024). However, atorvastatin reduced the relative risk of CHD events by 53% (HR 0.47, CI 0.32-0.69, P0.0001) among those allocated the amlodipine-based regimen, and by 16% (HR 0.84, CI 0.60-1.17, p: n.s.) among those allocated the atenolol-based regimen (P=0.025 for heterogeneity). There were no significant differences between the effects of atorvastatin on total cardiovascular events or strokes among those assigned amlodipine (HR 0.73, CI 0.60-0.88, P0.005 and HR 0.69, CI 0.45-1.06, P: n.s., respectively) or atenolol (HR 0.85, CI 0.71-1.02, P: n.s and HR 0.76, CI 0.53-1.08, P: n.s, respectively). Differences in blood pressure and lipid parameters (placebo corrected) between the two antihypertensive treatment limbs could not account for the differences observed in CHD outcome.These findings of an apparent interaction between atorvastatin and an amlodipine-based regimen in the prevention of CHD events are of borderline significance, and hence generate an hypothesis that merits independent evaluation in other trials.
- Published
- 2005
- Full Text
- View/download PDF